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Available online 5 November 2016Glioblastomamultiforme (GBM) remains the deadliest brain tumor in adults. GBM tumors are also notorious for
drug and radiation resistance. To inhibit GBMs more effectively, polymalic acid-based blood-brain barrier cross-
ing nanobioconjugateswere synthesized that are delivered to the cytoplasmof cancer cells and speciﬁcally inhib-
it themaster regulator serine/threonine protein kinase CK2 and the wild-type/mutated epidermal growth factor
receptor (EGFR/EGFRvIII), which are overexpressed in gliomas according to The Cancer Genome Atlas (TCGA)
GBM database. Two xenogeneic mouse models bearing intracranial human GBMs from cell lines LN229 and
U87MG that expressed both CK2 and EGFR at different levels were used. Simultaneous knockdown of CK2α and
EGFR/EGFRvIII suppressed their downstream prosurvival signaling. Treatment also markedly reduced the expres-
sion of programmed death-ligand 1 (PD-L1), a negative regulator of cytotoxic lymphocytes. Downregulation of
CK2 and EGFR also caused deactivation of heat shock protein 90 (Hsp90) co-chaperone Cdc37, whichmay suppress
the activity of key cellular kinases. Inhibition of either targetwas associatedwith downregulation of the other target
as well, which may underlie the increased efﬁcacy of the dual nanobioconjugate that is directed against both CK2
andEGFR. Importantly, the single nanodrugs, and especially the dual nanodrug,markedly suppressed the expression
of the cancer stem cell markers c-Myc, CD133, and nestin, which could contribute to the efﬁcacy of the treatments.
In both tumor models, the nanobioconjugates signiﬁcantly increased (up to 2-fold) animal survival compared with
the PBS-treated control group. The versatile nanobioconjugates developed in this study, with the abilities of anti-
cancer drug delivery across biobarriers and the inhibition of key tumor regulators, offer a promisingnanotherapeutic
approach to treat GBMs, and to potentially prevent drug resistance and retard the recurrence of brain tumors.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Glioblastoma multiforme (grade IV astrocytoma, GBM) accounts
for N50% of malignant gliomas [1]. Despite the advances in GBMrch Center, Department of
y Boulevard, AHSP-A8307, Los
sity of South Florida, Tampa, FL,
rnia Davis, Sacramento, CA, USA.
. This is an open access article undermanagement using surgery, radiation, and chemotherapy, recurrence
of these tumors is very frequent, and GBM remains a fatal disease. The
median survival time of GBM patients treated with radiation therapy
and temozolomide (TMZ) is approximately 15 months, with b10% of
the patients surviving for N5 years [2]. A key factor in the lack of
signiﬁcant improvement of therapeutic efﬁcacy during the past decade
is believed to be themolecular heterogeneity of GBMs.GBMprogression
has been associated with aberrant expression of vascular endothelial
growth factor (VEGF), epidermal growth factor receptor (EGFR), plate-
let-derived growth factor receptor (PDGFR), phosphatase and
tensin homolog deleted on chromosome 10 (PTEN), and other bio-
markers [3].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(TCGA) ResearchNetwork has reported that 57% of GBMs have EGFR al-
terations [4]. Moreover, TMZ-based treatment could activate EGFR and
its autophosphorylated variant EGFRvIII, and result in drug resistance
[5]. Downstream cascades of EGFR, including Ras-mitogen-activated
protein (MAP) kinase, phosphatidylinositol 3-kinase (PI3K) and its
downstream effector Akt kinase, and signal transducer and activator of
transcription (STAT), play important roles in proliferation, survival, mi-
gration, and angiogenesis of tumor cells. However, monotherapy with
the anti-EGFRmonoclonal antibody (mAb) cetuximab or the small mol-
ecule inhibitor erlotinib has shown minimal survival beneﬁt in clinical
trials [6,7].
Protein kinase CK2 (formerly, casein kinase II) is a ubiquitous serine/
threonine protein kinase that phosphorylates and interacts with N300
substrates involved in fundamental cellular functions. Studies have
shown that overexpression of CK2 potentiates tumor growth through
suppression of apoptosis, promotion of angiogenesis, and signaling
through PI3K-Akt and Wnt [8]. EGFR and Wnt pathways cross-talk
through CK2-mediated transactivation of β-catenin in human GBM
[9]. In addition, the TCGA database has revealed that 34% of 537 ana-
lyzed GBMs have an ampliﬁed CSNK2A1 gene that encodes the CK2 cat-
alytic α subunit (CK2α) [10].
Inmouse tumormodels, oral treatmentwith the small molecule CK2
inhibitor CX-4945 leads to downregulation of phosphorylated Akt, NF-
κB, STAT3, and Notch-1 [10–12]. Whereas CX-4945 is currently being
investigated in clinical trials (clinicaltrials.gov), it is anticipated that
gene therapy agents such as small interfering RNAs (siRNAs) or anti-
sense oligonucleotides (AONs) can be used to target CK2 more speciﬁ-
cally. Additionally, acquisition of tumor resistance to CX-4945 has
been reported [13]. Recently, tenﬁbgen nanoparticles for the delivery
of CK2 siRNA to head and neck cancers have been developed [14]. In a
xenograft model of hypopharyngeal squamous cell carcinoma, 50% of
treated mice survived for N6 months after 2 systemic administrations
of the nanoparticles at a dose of 0.01 mg/kg. Although these nanoparti-
cles are tumor-targeted, they might not readily pass through the blood
brain barrier (BBB), a necessary property for reaching brain tumors.
To effectively inhibit brain tumor growth, it is important to deliver
anti-cancer agents through biological barriers, including the BBB, that
are largely impenetrable to therapeutic antibodies and other large mol-
ecules. To address this challenge, nanobioconjugates to inhibit intracra-
nial GBMs in two mouse models have been created and synthesized in
this study. The nanobioconjugates presented here for cancer treatment
are novel nanotherapeutics in which all moieties are covalently con-
nected to poly(β-L-malic acid) (PMLA) and are sequentially functional
in cancer cells. Our biodegradable and non-toxic nanodrugs bind to
the receptors enriched on tumor vasculature and are able to cross the
BBB by transcytosis. Then, they speciﬁcally bind to cancer cells and
after internalization exit to the tumor cell cytoplasm from endosomes
using pH-sensitive endosomal disruption unit. These structural and
functional advantages make these nanobioconjugates different from
classical leaky and generally untargeted drug-encapsulating nanoparti-
cles such as liposomes or micelles [15–19].
These PMLA-based nanobioconjugates have a covalently conjugated
anti-transferrin receptor (a-TfR) mAb to target tumor vasculature and
allow the nanobioconjugate to be transcytosed through the BBB [17–
19]. After crossing the BBB, the nanobioconjugates need to be delivered
speciﬁcally to the EGFR-overexpressing GBM cells. To this end, the anti-
EGFRmAb cetuximabwas attached to the nanoplatform to facilitate the
crossing through the second biobarrier, the cancer cell membrane, and
deliver the inhibitors to the cytoplasm of the cancer cells. Morpholino
AONs against both CK2α (a catalytic subunit) and EGFR/EGFRvIII are
also attached to the nanobioconjugate for speciﬁc inhibition of expres-
sion of aberrant tumor genes. This study demonstrated that tumor de-
livery of EGFR and CK2α AONs or their co-delivery led to a signiﬁcant
increase of animal survival in two xenogeneic GBM mouse models,
with signiﬁcant reductions in several signaling proteins important fortumor cell proliferation and invasion. Additionally, these nanodrugs
were able to dramatically decrease the expression of several cancer
stem cell markers. To our knowledge, these are the ﬁrst nanobioconju-
gates that have been used to inhibit several pathways that converge
on cross-regulating EGFR and CK2. The data suggest that inhibition of
EGFR and/or CK2 with PMLA-based BBB-crossing nanobioconjugates is
a promising therapeutic strategy for GBM.2. Materials and methods
2.1. Cell lines and animals
Human glioblastoma cell lines LN229 and U87MG were obtained
from the laboratories ofW.K.C. and F.B.F. The cell lineswere authenticat-
ed by the American Type Culture Collection (ATCC) on March 1, 2016
using the short tandem repeat (STR) method. LN229 cells were 100%
identical to those in the ATCC database. U87MG were 93% identical,
with the only difference being related to gender (female rather than
male). This difference may be attributed to either the primer site muta-
tion or uncertain gender origin acknowledged by ATCC. Cells were cul-
tured in Dulbecco's modiﬁed Eagle medium (DMEM) containing 10%
fetal bovine serum (FBS), with penicillin (100 units/mL), streptomycin
(100 μg/mL), and amphotericin B (0.25 μg/mL), at 37 °Cwith 5% CO2. Fe-
male athymic NCr-nu/numice (6–8 weeks old) were obtained from the
National Cancer Institute (NCI) at Frederick (Frederick, Maryland, USA).2.2. Synthesis of PMLA nanobioconjugates
The synthesis of PMLA-based nanobioconjugates depicted schemat-
ically in Fig. 1A was performed in two major steps (Fig. 1B). In the ﬁrst
step, an intermediate (preconjugate) was prepared. Brieﬂy, pendant
carboxylates of PMLA were converted into an activated ester by con-
densing with N-hydroxysuccinimide (NHS) in the presence of
dicyclohexylcarbodiimide (DCC), followed by sequential replacement
of the activated ester through amide formation with mPEG5000-NH2
(methoxy polyethylene glycol [mPEG], 5 Mol-% with regard to malyl
units), leucine ethyl ester (LOEt, 40 Mol-% with regard to malyl units),
and 2-mercaptoethylamine (2-MEA, 5 Mol-% with regard to malyl
units). Mol-% of each component was calculated based on the total
moles of pendant carboxylates in the PMLA, which is 100% before the at-
tachment of any component. During the synthesis, knownmole amounts
of each component such as LOEt, AON, mAb, or mPEG were precisely
added. Percentage (%) of the nanobioconjugate loading was calculated
using the formula % = (mol component) / (mol malic acid) × 100. Each
addition of a reagent was followed by the addition of an equivalent
amount of triethylamine (TEA). To avoid any internal disulﬁde formation,
2-MEA was added together with equimolar amounts of dithiothreitol
(DTT). At this stage, the preconjugate is puriﬁed and can be stored at
−20 °C for several months without any loss of chemical activity.
In the second step, antibodies were attached by thioether formation
after introducing PEG-maleimide (PEG-MAL) linkers by known proce-
dures [18] followed by thiol reactive AONs to form disulﬁde linkages.
The thiol-reactive morpholino AONs (3′ amine modiﬁed) were pre-
pared by the reaction of the amino terminus with the N-succinimidyl
3-(2-pyridyldithio) propionate (SPDP) cross-linker and puriﬁed by
Sephadex LH-20 or PD-10 columns as described earlier [19]. The anti-
body and AON-containing nanobioconjugates were concentrated and
puriﬁed over Sephadex G-75 columns.
The physicochemical characterizations of the nanobioconjugates
(Supplemental Table S1) were performed by reversed phase high per-
formance liquid chromatography (HPLC; AONs), size exclusion chroma-
tography - HPLC (SEC-HPLC) and a Zetasizer Nano ZS90 (Malvern
Instruments Ltd., Malvern, UK). All analytical methods for the nanobio-
conjugate characterization were used as described earlier [18].
Fig. 1.Multifunctional nanobioconjugates used to treat glioblastoma multiforme (GBM). A) Schematic structure of the complete nanobioconjugate showing functional moieties. PMLA -
poly(β-L-malic acid), EGFR - epidermal growth factor receptor, AON - antisense oligonucleotide, PEG - polyethylene glycol, a-TfR - anti-mouse transferrin receptor to cross the BBB by
transcytosis , mAb - monoclonal antibody, Cetuximab - anti-human EGFR antibody to target tumor cells, CK2α - catalytic α subunit of protein kinase CK2. Scissors denote AON S-S
sites of cleavage from PMLA by cytoplasmic glutathione. B) Chemical synthesis of nanobioconjugate from PMLA through the preconjugate stage to the complete nanobioconjugate.
Percentage contents of functional units are shown. mPEG - methoxy polyethylene glycol.
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PMLAwasproduced from the culture broth of Physarumpolycephalum
[18] and puriﬁed over Sephadex G-25. The following AONswere custom-
synthesized by Gene Tools (Philomath, OR, USA): Morpholino-3′-NH2
AON1 (5′-CGGACAAAGCTGGACTTGATGTTT-3′) and AON2 (5′-
CCTGCTTGGCACGGGTCCCGACAT-3′) both targetingCK2αbut not a relat-
ed chain CK2α′, and 5′-TCGCTCCGGCTCTCCCGATCAATAC-3′ targeting
both the wild-type EGFR and the EGFRvIII variant [20]. Negative control
AONs were as follows: standard Gene Tools AON control (5′-
CCTCTTACCTCAGTTACAATTTATA-3′); unrelated AON to MMP-10 (5′-
GCATCATTCTCACTGCCCTTACCTT-3′); and AON having two mismatches
with CK2α (5′-CAGACAAAGCTGAACTTGATGTTT-3′). Rat anti-mouse
TfR/CD71 mAb (clone R17217) and anti-human EGFR chimeric (mouse/
human) mAb cetuximab were purchased from BioLegend (San Diego,
CA, USA) and Bristol-Myers Squibb (New York, NY, USA), respectively.
Unless otherwise speciﬁed, all chemicals and solvents of highest purity
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
2.4. In vitro gene inhibition by AONs
LN229 or U87MG cells were seeded in 6-well plates at 24 h before
treatment. To determine the efﬁcacy of gene inhibition, Endo-Porter
(4–6 μM; Gene Tools) and PMLA were used to deliver CK2α and EGFR
AONs at doses of 5–10 μM. The treatments with phosphate-buffered sa-
line (PBS), Endo-Porter alone and three unrelated AONs were used as
negative controls. The cells were maintained in DMEM (5% FBS)containing Endo-Porter/AON or PMLA-AON nanobioconjugates for
66 h or 96 h, respectively. Proteinswere then extracted from cell lysates
using T-PER Tissue Protein Extraction Reagent (ThermoFisher Scientiﬁc,
New York, NY, USA) buffer supplemented with phosphatase and cOm-
plete Mini protease inhibitor cocktail (Roche, Indianapolis, IN, USA)
for western blot analysis.
2.5. Intracranial tumor models and treatment with nanobioconjugates
All animal experiments were performed according to the guidelines
of the Institutional Animal Care and Use Committee (IACUC) at Cedars-
SinaiMedical Center (Los Angeles, CA, USA). LN229 cells (5× 105 cells in
a volume of 2 μL) or U87MG cells (2.5 × 104 cells in a volume of 2 μL)
were implanted intracranially into the right basal ganglia of athymic
nude mice. Three days after cell inoculation, 24 mice per cell line were
randomized into 4 groups and were treated with either PBS, P/Cetu/
CK2α [PMLA/PEG(5%)/LOEt(40%)/a-TfR(0.15%)/Cetuximab(0.15%)/
CK2α-AON(2.2%)], P/Cetu/EGFR [PMLA/PEG(5%)/LOEt(40%)/a-
TfR(0.15%)/Cetuximab(0.15%)/EGFR-AON(2.2%)], or P/Cetu/EGFR/
CK2α [PMLA/PEG(5%)/LOEt(40%)/a-TfR(0.15%)/Cetuximab(0.15%)/
EGFR-AON/CK2α-AON(2.2%)]. P refers to poly(β-L-malic acid, PMLA),
Cetu to anti-human EGFR mAb cetuximab to target human cancer
cells, a-TfR to mouse anti-transferrin receptor mAb to cross the mouse
BBB, and AON to antisense. The nanobioconjugates were injected intra-
venously, twice a week for 3 weeks, at a dose of 5 mg/kg of AON.When
IACUC-approved endpoints were reached, anesthetized mice were eu-
thanized by cervical dislocation followed by decapitation. Their brains
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2.6. Western blot analysis
Following the determination of tumormarginwith hematoxylin and
eosin staining, protein was extracted from OCT-embedded tissue using
T-PER buffer (Thermo Fisher Scientiﬁc) supplemented with phospha-
tase and cOmplete Mini protease inhibitor cocktail (Roche). Protein
concentration was determined by the bicinchoninic acid (BCA) method
(Pierce, Rockford, IL, USA). Sixmicrograms of protein extract were load-
ed on a NuPAGE Novex 4–12% Bis-Tris gel (Thermo Fisher Scientiﬁc)
and transferred to nitrocellulose membranes. The membranes were
blocked in Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE,
USA) and probed with primary and secondary antibodies. Primary anti-
bodies against CK2α/α′ (1:500, clone 1 AD9, Santa Cruz Biotechnology,
Dallas, TX, USA), EGFR (clone D38B1), phosphorylated Akt (clone D9E),
Akt (clone 40D4), c-Myc (clone D84C12), phosphorylated Cdc37 (clone
D8P8F), PD-L1 (clone E1L3N), and glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH; clone 14C10) (all at 1:1000, Cell Signaling Technol-
ogy, Inc., Beverly, MA, USA) were applied overnight at 4 °C in separate
reactions. The secondary antibodies used were anti-mouse IRDye 700-
or anti-rabbit IRDye 800-labeled (LI-COR Biosciences). The membranes
were imaged using an IR-excited ﬂuorescence system (Odyssey CLx)
and the band intensities were quantiﬁed using Image Studio 4.0 soft-
ware (both from LI-COR Biosciences).
2.7. Immunostaining
Frozen tissue blocks were sectioned at 7–10 μm thickness using a
Leica CM3050 S cryostat (Leica Biosystems, Inc., Buffalo Grove, IL,
USA). When ready for staining, tissue sections were air-dried at room
temperature, ﬁxed with ice-cold acetone for 10 min or 1% paraformal-
dehyde for 5 min, and then rinsed three times with PBS. Sections were
incubated in a humidiﬁed chamber with blocking buffer (4% normal
goat serum, 4% normal donkey serum, 1% BSA and 0.1% Triton X-100
in PBS) for 1 h at room temperature to block non-speciﬁc interactions.
Non-speciﬁc binding induced by endogenous mouse immunoglobulin
was blocked by Vector M.O.M. Blocking Reagent (Vector Laboratories,
Burlingame, CA, USA). The blocked sections were incubated overnight
at 4 °C with primary antibodies diluted in staining buffer, and later
washed with PBS. Secondary antibodies for labeling were incubated
for 1 h and sectionsmountedwith ProLongGold Antifade (Thermo Fish-
er Scientiﬁc) mounting medium containing 4′,6-diamidino-2-
phenylindole (DAPI) to counterstain cell nuclei. The samples were
stained for CK2α/α′ (clone 1 AD9, Santa Cruz Biotechnology), EGFR
(clone ICR10, Abcam, Cambridge,MA, USA), EGFRvIII (clone L8A4, Abso-
lute Antibody Ltd., Cleveland, UK), and the cancer stem cell markers: c-
Myc (clone9E10, Abcam), Nestin (clone rat-401, EMDMillipore, Temec-
ula, CA, USA), and CD133 (clone 17A6.1, EMD Millipore). Anti-mouse
IgG TRITC and anti-rat IgG FITC (both from Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA, USA), and anti-mouse IgG FITC
(EMD Millipore) were used as secondary antibodies. Images were cap-
tured using a Leica DM6000 B microscope (Leica Microsystems, Inc.,
Buffalo Grove, IL, USA).
2.8. Statistical analysis
Statistical analyses were performed using GraphPad Prism 6
(GraphPad Software, Inc., La Jolla, CA, USA). One-way ANOVA followed
by the Dunnett post hoc test was used to analyze 3 or more groups,
and the Student t test was used for 2 groups, with a signiﬁcance thresh-
old of P b 0.05. Animal survivalwas analyzed using the Kaplan-Meier es-
timate (log-rank test). All data are presented asmeans± standard error
of the means (SEM).3. Results
3.1. Inhibition of tumor markers CK2α and EGFR by AONs in GBM cell lines
The expression of CK2α and EGFR in GBM cell lines LN229 and
U87MGwas determined bywestern blot. Both cell lines showed speciﬁc
bands, but U87MG had an elevated level of EGFR compared to LN229,
whereas the CK2α level was much lower in U87MG than in LN229
(Fig. 2A). The efﬁciency of two CK2α-targeting morpholino AONs was
tested in LN229 cells. Both AONs downregulated CK2α in a dose-depen-
dent manner (Fig. 2B). However, because AON1 was somewhat
more effective than AON2 at both concentrations (5 and 10 μM),
only AON1 was used further for the nanobioconjugate synthesis.
Three negative control AONs did not affect the expression of CK2α
(Supplemental Fig. S1). The efﬁcacy of the entire nanobioconjugates
bearing CK2α or EGFR AONs was further tested in both cell lines
for CK2α inhibition (Fig. 2C). The nanobioconjugate-attached AON
against CK2α (P/Cetu/CK2α) was able to inhibit the expression
of CK2α in LN229 and U87MG cells (Fig. 2C). In agreement with
previous reports that showed CK2 downstream from EGFR activation
[9,11], the conjugated AON against EGFR (P/Cetu/EGFR) also resulted
in a reduction of CK2α protein expression, with a similar potency to
the AON against CK2α. Maximum inhibition with both AONs was
observed at 7.5 μM.
3.2. Increased tumor-bearing animal survival and downregulation of mo-
lecular targets upon treatment with nanobioconjugates
Survival rates were examined in mice with intracranial LN229 or
U87MG tumor xenografts that had been treated with nanobioconju-
gates with covalently attached AONs to either CK2α (P/Cetu/CK2α) or
EGFR (P/Cetu/EGFR) individually or to both simultaneously (P/Cetu/
EGFR/CK2α) (Fig. 3A). In mice with LN229 tumors, the median survival
time of PBS-treated groupwas 37 days. Treatmentwith P/Cetu/CK2α, P/
Cetu/EGFR, or P/Cetu/EGFR/CK2α signiﬁcantly prolonged median sur-
vival times vs. PBS group to 70 days (P= 0.001), 63 days (P= 0.015),
or 75 days (P b 0.002), respectively (Fig. 3B). In mice with U87MG tu-
mors, the PBS-treated group had a median survival time of 34 days
(Fig. 3B). Treatment with P/Cetu/CK2α increased the median survival
time to 48 days (P b 0.05), whereas P/Cetu/EGFR increased survival to
50 days (P b 0.002) and P/Cetu/EGFR/CK2α, to 56 days (P b 0.002) vs.
PBS group (Fig. 3B). Morphological analysis of treated tumors revealed
well-developed invading tumors in the PBS-treated group, whereas
nanobioconjugate-treated tumors had extensive areas of tissue necrosis
(Fig. 3C; LN229).
CK2 is an important protein kinase that phosphorylates manymem-
bers of EGFR downstream cascades, such as the PI3K-Akt pathway or the
Ras-MEK pathway. To determine the correlation between antitumor ef-
ﬁcacy and downregulation of targets in EGFR signaling pathways, pro-
teins were extracted from three or more tumor specimens in each
treatment group and were analyzed by western blot using GAPDH as
an internal control. The treatment with P/Cetu/CK2α not only reduced
the CK2α protein level by 30%, but it also attenuated the expression of
EGFR by 50% compared with the PBS control (Fig. 4A, B). P/Cetu/EGFR-
treated tumors showed downregulation of EGFR protein by 90%, but
also a decrease of CK2α by 65%, suggesting that there is cross-talk be-
tween EGFR and CK2. Interestingly, P/Cetu/EGFR had a greater inhibito-
ry effect on the expression of CK2α than P/Cetu/CK2α (65% vs. 30%,
respectively). Compared to these constructs, the nanobioconjugate
that combined AONs targeting both CK2α and EGFR reduced the ex-
pression of CK2α and EGFR by 70% and 95%, respectively.
In addition to CK2α and EGFR, the activities of their downstream ef-
fectors were also investigated. The treatment with nanobioconjugates
led to reduced phosphorylation of Akt and c-Myc, which are essential
for tumor growth (Fig. 4A, B). The P/Cetu/CK2α modestly decreased
phosphorylated/activated Akt (pAkt), but P/Cetu/EGFR signiﬁcantly
Fig. 2. Target protein expression and its inhibition induced by free AONs and PMLA-based nanobioconjugates. AON - antisense oligonucleotide, PMLA - poly(β-L-malic acid). Top of each
panel:western blot; bottomof eachpanel: quantitative evaluation. A) Expression of EGFR andCK2α proteins in LN229 andU87MG cells revealed bywestern blot analysiswith GAPDHas a
housekeeping control. Note higher expression of EGFR compared to CK2α in U87MG cells, with the opposite situation in LN229 cells. EGFR - epidermal growth factor receptor, CK2α -
catalytic α subunit of protein kinase CK2, GAPDH - glyceraldehyde 3-phosphate dehydrogenase. B) Decreased expression of CK2α in LN229 cells after the action of two different AONs
for 4 days. CK2α AON1 was signiﬁcantly active at 5 and 10 μM, whereas CK2α AON2 was only active at 10 μM. Subsequent experiments were thus conducted with only AON1. C)
Efﬁcacy of CK2α inhibition in LN229 and U87MG cells was examined with nanobioconjugates containing AON1 against CK2α or AON against EGFR. Both nanobioconjugates showed
inhibition of CK2α expression at a 7.5 μM concentration of the conjugated AON, especially in LN229 cells. Cetu - cetuximab, P/Cetu/EGFR - nanobioconjugate with AON against EGFR,
P/Cetu/CK2α - nanobioconjugate with AON against CK2α.
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achieved with P/Cetu/EGFR/CK2α. The expression of c-Myc was signiﬁ-
cantly suppressed by all three nanobioconjugates, with P/Cetu/EGFR/
CK2α being the most active (over 85% inhibition). Interestingly, the in-
hibition of heat shockprotein 90 (Hsp90) co-chaperoneCdc37 observed
upon all treatments positively correlated with the CK2α and EGFR
downregulation. This observation corroborates previous data [11,21]
on the important role of Cdc37 in the regulation of CK2 and EGFR signal-
ing. In addition, we found that programmed death-ligand 1 (PD-L1),
which could suppress anti-tumor immunity, was also signiﬁcantly re-
duced by the inhibition of EGFR and/or CK2α (Fig. 4A, B).
To further validate the results of western blot, protein expression of
CK2α and EGFR was also examined by immunohistochemistry on
mouse brain tumor cryosections (Fig. 5). Consistent with the above ob-
servations, P/Cetu/CK2α and especially P/Cetu/EGFR signiﬁcantly atten-
uated the expression of CK2α, EGFR, and EGFRvIII. The combination
therapy using P/Cetu/EGFR/CK2α resulted in a virtually complete lack
of immunostaining for these proteins (Fig. 5). Unlike the AON that
was speciﬁc for only CK2α, the mAb used for immunostaining also rec-
ognized theα′ subunit of CK2. Based on the staining patterns, it may be
concluded that this subunitwas also downregulated by thenanobiocon-
jugate treatments.
3.3. Reduction of cancer stem cell population by nanobioconjugates
As many other tumors, gliomas comprise a cancer stem cell (CSC)
population mainly responsible for tumor recurrence and poor disease
prognosis [22]. These CSCs have several markers with high expressionlevels correlating with decreased patient survival. Therefore, it is of
major interest to monitor the tumor treatment effects on the levels of
the most common CSC markers including c-Myc, CD133, and nestin
[22]. Upregulated c-Myc is not only correlatedwith advancedmalignan-
cy and poor patient prognosis, but is also vital for the survival and self-
renewal of CSCs [22]. CD133/prominin-1 is a neural progenitor marker
associated with GBM invasion. Recurrent GBMs contain an increased
percentage of CD133+ cells compared to the primary tumor, and
many of these cells co-express nestin [22]. Nestin is a member of the in-
termediate ﬁlament superfamily and a stem cell marker. Its increased
expression has been associated with higher-grade gliomas and lower
patient survival rates [22]. For these reasons, we have used these
markers to examine the effects of our treatment on CSCs.
To determine the activity of nanobioconjugates against CSCs, the per-
tinent markers CD133, c-Myc, and nestin were immunohistochemically
detected on the tumor cryosections. As shown in Fig. 6, the inhibition of
EGFR and CK2α, alone or in combination, caused a dramatic reduction
in immunostaining for all three markers. The combination treatment ap-
peared to completely abolish the staining for all three markers. The data
suggest that by blocking CK2α and/or EGFR, CSCs can be markedly sup-
pressed, which could translate into a lower recurrence of GBMs.
4. Discussion
In recent years, the concept of targeted cancer therapy has signiﬁ-
cantly changed. Common small molecule treatments target a speciﬁc
tumor molecular marker to modulate its expression in a desired way
but have no tissue speciﬁcity, often resulting in serious side effects
Fig. 3. Nanobioconjugate treatment of mice bearing intracranial LN229 and U87MG human GBM tumors. A) Kaplan-Meier survival curves (log-rank test) show signiﬁcantly prolonged
survival of LN229 and U87MG tumor-bearing mice upon treatment with AONs targeting CK2α, EGFR, or EGFR + CK2α combined on a single nanobioconjugate. The results represent
means ± SEM vs. PBS treatment. *, P b 0.05; **, P b 0.01. AON - antisense oligonucleotide, CK2α - catalytic α subunit of protein kinase CK2, EGFR - epidermal growth factor receptor,
PBS - phosphate-buffered saline, Cetu - cetuximab, P/Cetu/CK2α - nanobioconjugate with AON against CK2α, P/Cetu/EGFR - nanobioconjugate with AON against EGFR, P/Cetu/EGFR/
CK2α - nanobioconjugate with AONs against both EGFR and CK2α. B) Median survival times (days) of the different groups of mice showed signiﬁcant effects of all nanobioconjugates
in both LN229 and U87MG GBMs compared with PBS-treated mice, according to the log-rank test. C) Hematoxylin and eosin staining of LN229 tumor sections after treatment.
Compared with the PBS control, treatment with all nanobioconjugates resulted in the appearance of necrotic areas within the tumor and reduced the GBM cellularity. The
nanobioconjugate with the combination of AONs against CK2α and EGFR produced a stronger effect than single nanobioconjugates.
19S.-T. Chou et al. / Journal of Controlled Release 244 (2016) 14–23because they also act on normal tissues. In contrast, nanomedicine of-
fers targeting possibility not only in terms of a speciﬁc gene/protein af-
fected, but also in terms of acting on a speciﬁc tissue or a speciﬁc tumor,
whichwould result in fewer side effects. Nanodrugs often enter the tar-
get cells by bypassingmembrane pumps or using differentmechanisms
of delivery across cell membranes, thereby signiﬁcantly lowering the
probability of drug resistance development [23]. Additionally, next-gen-
eration nanomedicines can pass through biological barriers and offer
combined drug treatment using a single delivery vehicle, enhancing
the tumoricidal effect [17]. In this report, we engineered nanobioconju-
gate drugs that were able to pass through the BBB and deliver to intra-
cranial tumors antisense inhibitors of key GBMmarkers identiﬁed from
the TCGA GBM database, i.e. EGFR (both wild type and the mutated
EGFRvIII) and the master regulator protein kinase CK2 [4,10]. These
new nanodrugs were tested in two xenogeneic models of orthotopic in-
tracranial human GBMswith high- and low-level expression of CK2 and
EGFR.
All used nanodrugs (against either CK2α or EGFR or both)were able
to signiﬁcantly prolong the survival of tumor-bearing animals in both
GBM models, with similar results (Fig. 3). The dual nanobioconjugate
(P/Cetu/EGFR/CK2α) showed a tendency for a stronger inhibiting effect
towards the downstream signaling intermediates of CK2 and EGFR
pathways including pAkt, pCdc37, and c-Myc, as well as PD-L1 (Fig. 4).
The LN229 glioma cell line expressed a high level of CK2α and a low
level of EGFR, whereas the U87MG glioma cell line had a low level of
CK2α and high level of EGFR in vitro (Fig. 2A). The in vivo treatment re-
sults (Fig. 3) are in line with these levels, with the anti-CK2α nanodrug
being more effective in LN229, whereas the anti-EGFR nanodrug was
somewhat more effective in U87MG. The dual nanobioconjugate was
similar to single nanodrugs in promoting animal survival for both glio-
mas. This may be partially explained by cross-talk between CK2 and
EGFR downstream signaling [11]. It should also be noted, that the dualnanodrug had only half of the concentration of each AON to either
CK2α or EGFR compared to single nanodrugs. Therefore, it allowed to
substantially lowering the dose of each AON with the same anti-tumor
effect. This is one of the main advantages of nanotherapy aimed at re-
ducing drug toxicity and side effects for non-targeted tissues generally
seen at higher drug doses. This nanodrug design and development
could be also important for glioma treatment in the clinicwhen patients
have a heterogeneous tumor genotype.
Noteworthy, the anti-CK2αnanodrug reduced CK2αprotein expres-
sion by 30%, but the anti-EGFR treatment resulted in a greater inhibition
(65%). Likewise, CK2α inhibition also resulted in signiﬁcant EGFR
downregulation. This phenomenon was previously described in tumor
cell cultures [11,24] and was observed here for the ﬁrst time in
nanodrug-treated brain tumors. There may be several mechanisms un-
derlying this cross-inhibition. In the case of the anti-CK2α nanodrug,
the tumor cell-targeting anti-EGFR mAb cetuximab could contribute to
partial downregulation of EGFR. A more general mechanism may in-
volve cross-talk and convergence of downstream pathways of these
two powerful signaling mediators [11]. Additionally, there is a subset
of microRNAs that inhibit both CK2α and EGFR (e.g., miR-211, miR-
571, and miR-7110), and these are all decreased in more aggressive
GBMs and lung cancers [25–27]. These ﬁndings may suggest that
nanodrug inhibition of one target allows the remaining miRNA to
more efﬁciently inhibit the other target, thereby potentiating the effect.
Treatment with P/Cetu/CK2α modestly downregulated the phos-
phorylation of prosurvival Akt at Ser473, in agreement with earlier
data using a small molecule CK2 inhibitor [28,29]. However, phosphor-
ylation at other sites in Akt is also important for its activation by CK2
[28]. As direct EGFR targeting decreases Akt phosphorylation at
Thr308 and Ser483, the dual nanobioconjugate P/Cetu/EGFR/CK2α
could mediate synergistic abrogation of Akt phosphorylation (Fig. 4A)
at all three key residues, enhancing the anti-tumor effect. Moreover,
Fig. 4. Expression of molecular targets in xenogeneic LN229 brain tumors revealed by western blot. A) Protein expression of EGFR, CK2α, phosphorylated Akt [Ser473] (pAkt S473), total
Akt, c-Myc, phosphorylated Cdc37 (pCdc37), and programmed death-ligand 1 (PD-L1). Treatment with all nanobioconjugates resulted in signiﬁcantly lower expression of the analyzed
proteins. Three independent tumor specimens per each treatment group were analyzed. AON - antisense oligonucleotide, PBS - phosphate-buffered saline, Cetu - cetuximab, CK2α -
catalytic α subunit of protein kinase CK2, EGFR - epidermal growth factor receptor, P/Cetu/CK2α - nanobioconjugate with AON against CK2α, P/Cetu/EGFR - nanobioconjugate with
AON against EGFR, P/Cetu/EGFR/CK2α - nanobioconjugate with AONs against both EGFR and CK2α, GAPDH - glyceraldehyde 3-phosphate dehydrogenase. B) Band intensities of tumor
samples were quantiﬁed by Image Studio software and normalized against GAPDH or Akt (for pAkt) as a control. All proteins showed statistically signiﬁcant decreases following the
treatments. Note signiﬁcantly reduced expression of EGFR upon anti-CK2α treatment and vice versa. The results represent means ± SEMs vs. PBS treatment. *, P b 0.05; **, P b 0.01;
***, P b 0.001.
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and Hsp90 [30]. CK2 also plays a crucial role in the activation of the
Hsp90/Cdc37 complex forming a positive feedback loop with Akt and
other kinases. In addition to Akt, CK2-dependent phosphorylation of
Cdc37 facilitates the activation of other EGFR downstream effectors in-
cluding Raf and Src [31]. Blocking CK2 could thus indirectly affect
EGFR signaling through downregulation of Cdc37 observed after nano-
bioconjugate treatment (Fig. 4A), and also through inhibition of other
pathways including the PTEN-dependent pathway [32,33]. This cross-
talk could also be the basis of angiogenic signaling through CK2 and
EGFR [34,35].
Importantly, we have observed signiﬁcant downregulation of the
immune response modulator PD-L1 in treated GBMs. The PD-1/PD-L1
signaling that leads to an immunosuppressive tumor microenviron-
ment and progressive tumor proliferation has been extensively studied
[36]. ThemAb nivolumab that neutralizes PD-1 is currently under inves-
tigation in clinical trials to treat multiple cancers. The expression of PD-
L1/B7-H1 by glioma cells reduces the number of tumor inﬁltrating lym-
phocytes and is correlated with advanced glioma grade [37,38]. In our
experiments, an 80% inhibition of PD-L1 that was observedwhile simul-
taneously targeting CK2α and EGFRmight be attributed to the inactiva-
tion of Akt [39]. The ability to downregulate PD-L1 makes the used
nanobioconjugates appealing therapeutic agents to restore impaired
anti-tumor T cell function.An important ﬁnding in this study was a pronounced suppression of
several CSC markers in GBMs upon treatment with nanobioconjugates
(Figs. 4A, 6). Cancer stem cells may be mainly responsible for the GBM
recurrence as they are more resistant to conventional tumor therapies
[22,40,41]. CK2 is not only linked to sustained growth of GBMs, but is
also involved in themaintenance of cancer stemcells through activation
of Notch, Wnt/β-catenin, or Hedgehog/Gli1 signaling [42–45]. For in-
stance, siRNA-mediated inhibition of CK2 is associated with decreased
transcriptional activities of Gli1 and the Notch receptor intracellular do-
main in lung cancers [12,45]. The reduction of nestin observed upon
nanobioconjugate treatment (Fig. 6) suggests that Notch signaling
may be inhibited by the AON against CK2α [46]. At the same time the
EGFR family members and Notch signaling are deregulated in many
human cancers [47]. β-catenin that can be regulated by CK2 plays a cen-
tral role inWnt signaling. Stabilized β-catenin translocates to the nucle-
us, forming a complex with DNA-bound T cell factor/lymphoid
enhancing factor to activate Wnt signaling [48]. Several groups have
found that β-catenin is prevented from degradation by CK2-mediated
phosphorylation at Thr393 [49,50]. Moreover, the interaction of CK2α
and ERK2 facilitates the phosphorylation of α-catenin at S641, which
promotes the transcriptional activity of β-catenin [9]. Furthermore, re-
duced CK2 activity leads to the inhibition of two β-catenin-regulated
stem cell genes,OCT4 and NANOG, resulting in decreased tumorigenesis
and expression of the CSC marker CD133 as an indicator of GBM cell
Fig. 5. Expression of CK2α/α′, EGFR, and EGFRvIII in frozen sections of LN229 tumors revealed by immunohistochemistry. Nuclei were counterstained with DAPI. The nanobioconjugates
causedmarked inhibition of the expression of all targets. The P/Cetu/CK2α nanobioconjugate strongly inhibited the expression of CK2 andmoderately inhibited the expression of EGFR and
EGFRvIII. In accordance with the western blot data, the other nanobioconjugates were more effective, especially the dually targeted nanobioconjugate (P/Cetu/EGFR/CK2α).
Representative pictures are shown. Scale bar = 10 μm. AON - antisense oligonucleotide, PBS - phosphate-buffered saline, Cetu – cetuximab, CK2α - catalytic α subunit of protein
kinase CK2, EGFR - epidermal growth factor receptor, EGFRvIII – mutated EGFR, P/Cetu/CK2α - nanobioconjugate with AON against CK2α, P/Cetu/EGFR - nanobioconjugate with AON
against EGFR, P/Cetu/EGFR/CK2α - nanobioconjugate with AONs against both EGFR and CK2α.
21S.-T. Chou et al. / Journal of Controlled Release 244 (2016) 14–23proliferation [51]. In addition to CK2, EGFR is also involved in survival
and self-renewal of GBM cancer stem cells. It was reported that EGFR
or EGFRvIII activation of Akt results in phosphorylation of Smad5 and
overexpression of inducer of differentiation 3 (ID3), which promotesFig. 6. Expression of cancer stem cell markers CD133, c-Myc, and nestin in frozen sections of LN2
nanobioconjugates caused marked inhibition of the expression of all targets, especially the du
Scale bar = 10 μm. AON - antisense oligonucleotide, PBS - phosphate-buffered saline, Cetu -
factor receptor, P/Cetu/CK2α - nanobioconjugate with AON against CK2α, P/Cetu/EGFR - nano
against both EGFR and CK2α.the emergence of glioma stem-like cells in primary astrocytes [52]. Ad-
ditionally, EGFR cross-communicates with β-catenin through interme-
diates including STAT3 and Akt [53]. Interestingly, inhibition of STAT3
causes downregulation of nestin in GBMs, suggesting dependence on29 tumors revealed by immunohistochemistry. Nuclei were counterstainedwith DAPI. All
ally targeted nanobioconjugate (P/Cetu/EGFR/CK2α). Representative pictures are shown.
cetuximab, CK2α - catalytic α subunit of protein kinase CK2, EGFR - epidermal growth
bioconjugate with AON against EGFR, P/Cetu/EGFR/CK2α - nanobioconjugate with AONs
Fig. 7. A schematic diagram illustrating the possible interplay between the EGFR and CK2 signaling pathways that regulate GBM cell proliferation. An attached “P” indicates
phosphorylation. PD-L1 - programmed death-ligand 1, EGFR - epidermal growth factor receptor, Hsp90 - heat shock protein 90, Cdc37 - co-chaperone of Hsp90, Akt - a serine/
threonine protein kinase, CK2 - protein kinase CK2, NICD - intracellular domain of the Notch receptor, PTEN - tensin homolog deleted on chromosome 10, Gli1 - glioma-associated
oncogene homolog 1 (zinc ﬁnger protein). Nestin and c-Myc are cancer stem cell markers important for glioma invasion. Catenins are cell-cell adhesion proteins; β-catenin also
regulates transcription and is part of the Wnt signaling pathway that regulates cell proliferation and migration.
22 S.-T. Chou et al. / Journal of Controlled Release 244 (2016) 14–23EGFR activation [54]. Downregulation of CSC markers in GBMs upon
treatment with our nanobioconjugates may thus result from inhibition
of these multiple pathways.
In summary, using two mouse models of intracranial glioma, we
demonstrated signiﬁcantly increased survival of tumor-bearing animals
upon systemic treatment with tumor-targeted nanobioconjugates that
inhibited CK2α and/or EGFR. The molecular mechanisms underlying
this effect (Fig. 7) may be related to the profound inhibition of several
converging prosurvival signaling pathways and inhibition of the expres-
sion of several cancer stem cell markers in treated gliomas (Fig. 6). The
nanobioconjugate that provided simultaneous inhibition of CK2α and
EGFR showed the strongest inhibition of its intended targets and down-
stream signaling pathways and may be further considered for transla-
tional applications, along with other new developments including
immunotherapy [47].
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